Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Official Summary
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.
Study Design
- Study Type: OBSERVATIONAL
- Enrollment: 1,141 participants
Primary Outcomes
- Rate of change in cognition as measured by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13) (5 years)
- Rate of change in cognition as measured by the Logical Memory Test I and II (5 years)
- Rate of change in cognition as measured by the Mini-Mental State Examinations (MMSE) (5 years)
Secondary Outcomes
- Rate of change in cognition as measured by the Cogstate Brief Battery (CBB) (5 years)
- Rate of change in cognition as measured by the American National Adult Reading Test (ANART) (5 years)
- Rate of change in cognition as measured by the Montreal Cognitive Assessment (MoCA) (5 years)
- Rate of change in cognition as measured by the Rey Auditory Verbal Learning Test (5 years)
- Rate of change in cognition as measured by the Trail Making Test: A and B (5 years)
Trial Locations
- University of Alabama, Birmingham, Birmingham, Alabama, United States
- Banner Alzheimer's Institute, Phoenix, Arizona, United States
- Barrow Neurological Institute, Phoenix, Arizona, United States
- Banner Sun Health Research Institute, Sun City, Arizona, United States
- University of California, Irvine, Irvine, California, United States
- University of California, San Diego, La Jolla, California, United States
- Long Beach VA Neuropsychiatric Research Program, Long Beach, California, United States
- University of Southern California, Los Angeles, California, United States
- University of California, Los Angeles, Los Angeles, California, United States
- VA Palo Alto HSC / Stanford School of Medicine, Palo Alto, California, United States
- ...and 10 more locations
More Mild Cognitive Impairment (MCI) Trials
AI-generated analysis for educational purposes only. This is not medical advice. Discuss clinical trial participation with your doctor. Data sourced from ClinicalTrials.gov.